In this pilot study, we compared the differences in serum levels of Gal-9, sTIM-3, FABP1, and FABP4 between RA patients and healthy participants, and between RA patients with none-to-mild and moderate-to-severe NAFLD. The gene discussed is FABP1; the disease is metabolic dysfunction-associated steatotic liver disease.